nach oben

Medical Oncology

Erschienen in:

01.01.2015 | Original Paper

Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter?

verfasst von: Wenxi Yu, Lina Tang, Feng Lin, Yang Yao, Zan Shen

Erschienen in: Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma. But its role in neoadjuvant/adjuvant chemotherapy of osteosarcoma is still not defined. We conducted a retrospective evaluation of THP-containing chemotherapy for osteosarcoma in comparison with ADM-containing chemotherapy to determine differences in efficacy and toxicities between THP- and ADM-containing regimens. From January 2008 to May 2011, 112 stage IIB limb high-grade osteosarcoma patients were treated in our institute. Fifty-four patients received a median 6 cycles of neoadjuvant/adjuvant chemotherapy consisted of THP (pirarubicin), DDP (cisplatin), IFO (ifosfamide) and MTX (methotrexate), while 58 patients received a median 6 cycles of neoadjuvant/adjuvant chemotherapy consisted of ADM (doxorubicin), DDP (cisplatin), IFO (ifosfamide) and MTX (methotrexate). Efficacy and toxicity of the 2 anthracyclines given as combination chemotherapy were assessed in these patients. The limb salvage rate, histologic response rate, 2-year recurrence rate, 2-year metastasis rate, 2-year disease-free survival rate, 2-year overall survival rate, median disease-free survival time (DFS) and median overall survival time (OS) in THP-containing group were similar to that in ADM-containing group. Toxicities were well balanced in two groups. No death related to chemotherapy was observed. Left ventricular ejection fraction was unchanged 1 and 2 years after chemotherapy in two groups. Efficacy and toxicity of THP-containing combination are similar to those of ADM-containing combination in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma.

Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341(5):342–52.PubMedCrossRef

Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9(8):893–9.PubMedCrossRef

Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18(24):4016–27.PubMed

Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP. Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21(8):1574–80.PubMedCrossRef

Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, Stenwig AE, Willén H, Holmström T, Follerås G, Brosjö O, Kivioja A, Jonsson K, Monge O, Saeter G. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39(4):488–94.PubMedCrossRef

Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):137–9.PubMed

Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7.CrossRef

Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo). 1979;32(10):1082–4.CrossRef

Mori M, Kitamura K, Masuda M, Hotta T, Miyazaki T, Miura AB, Mizoguchi H, Shibata A, Saito H, Matsuda T, Masaoka T, Harada M, Niho Y, Takaku F. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol. 2005;81(3):246–54.PubMedCrossRef

10.

Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H. Apoptosis in young rats with adriamycin-induced cardiomyopathy–comparison with pirarubicin, a new anthracycline derivative. Pediatr Res. 2002;51(2):256–9.PubMedCrossRef

11.

Herait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue—are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer. 1992;28A(10):1670–6.PubMedCrossRef

12.

Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo). 1979;32(10):1085–6.CrossRef

13.

Pouna P, Bonoron AS, Gouverneur G, Tariosse L, Besse P, Robert J. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemother Pharmacol. 1995;35:257–61.PubMedCrossRef

14.

Hirano S, Wakazono K, Agata N, Iguchi H, Tone H. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Drugs Exp Clin Res. 1994;20:153–60.PubMed

15.

Okada Y, Horikawa K, Sano M. Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy. Gan To Kagaku Ryoho. 1997;24:585–9.PubMed

16.

Liu SY, Song SX, Lin L, Liu X. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy. 2010;56(2):101–7.PubMedCrossRef

17.

Zheng SE, Xiong S, Lin F, Qiao GL, Feng T, Shen Z, Min DL, Zhang CL, Yao Y. Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin. 2012;33(6):832–8.PubMedCentralPubMedCrossRef

18.

He A, Qi W, Huang Y, Sun Y, Shen Z, Zhao H, Yang Y, Yao Y. Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. Int J Clin Oncol. 2013;18(3):498–505.PubMedCrossRef

19.

Qi WX, He AN, Tang LN, Shen Z, Yao Y. Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol. 2012;29(3):2229–33.PubMedCrossRef

20.

Zhao H, Yao Y, Wang Z, Lin F, Sun Y, Chen P. Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. J Chemother. 2010;22(2):119–24.PubMedCrossRef

21.

Futani H, Fukunaga S, Tsukamoto Y, Terada N, Ono J, Okamoto N, Otsuka Y, Tanizawa T, Tomatsuri M, Yoshiya S. Small cell osteosarcoma successfully treated by high-dose ifosfamide and methotrexate, combined with carboplatin and pirarubicin. Anticancer Res. 2012;32(3):965–71.PubMed

22.

Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K. Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother. 2002;36(6):996–9.PubMedCrossRef

23.

Lin F, Wang Q, Yu W, Tang L, Zheng S, Sun Y, Shen Z, Yao Y, Dong Y. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 2011;7(3):270–5.PubMedCrossRef

24.

Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, Bertoni F, Guerra A, Capanna R, Albisinni U. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer. 1985;56(7):1515–21.PubMedCrossRef

25.

Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19:292–315.PubMedCrossRef

26.

Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R, Dominkus M, Saeter G. Osteosarcoma over the age of forty. Eur J Cancer. 2003;39(2):157–63.PubMedCrossRef

27.

Campanacci M, Enneking WF. High grade osteosarcomas. In: Bone and soft tissue tumors. Second, completely revised edition by Piccin Nuova Libraria S.p.A, Padova, Italy. New York: Springer; 1999. p. 464–8.

28.

Damron TA, Ward WG, Steward MA. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. National cancer data base report. Clin Orthop Relat Res. 2007;459:40–7.PubMedCrossRef

29.

Bacci G, Ferrari S, Donati D, Longhi A, Bertoni F, Di Fiore M, Comandone A, Cesari M, Campanacci M. Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep. 1998;5(5):1259–63.PubMed

Titel: Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter?
verfasst von: Wenxi Yu
Lina Tang
Feng Lin
Yang Yao
Zan Shen
Publikationsdatum: 01.01.2015
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 1/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0307-y

Springer Medizin

Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter?

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer

Correlation and malignant transformation of MSCs with the overexpression of SIL-R/GP130 under the tumor microenvironment

Anorectal malignant melanoma: retrospective analysis of management and outcome in a single Portuguese Institution

CrkL regulates SDF-1-induced breast cancer biology through balancing Erk1/2 and PI3K/Akt pathways

MiR-145 acts as a metastasis suppressor by targeting metadherin in lung cancer

The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie